scispace - formally typeset
S

Sóstenes Mistro

Researcher at Federal University of Bahia

Publications -  32
Citations -  308

Sóstenes Mistro is an academic researcher from Federal University of Bahia. The author has contributed to research in topics: Medicine & Diabetes mellitus. The author has an hindex of 6, co-authored 24 publications receiving 218 citations.

Papers
More filters
Journal ArticleDOI

Comparative Study of rK39 Leishmania Antigen for Serodiagnosis of Visceral Leishmaniasis: Systematic Review with Meta-Analysis

TL;DR: The rK39 protein used either in a strip test or in an ELISA, and the DAT are the best choices for implementation of rapid, easy and efficient test for serodiagnosis of VL.
Journal ArticleDOI

Does Lipid Emulsion Reduce Amphotericin B Nephrotoxicity? A Systematic Review and Meta-analysis

TL;DR: It is revealed that amphotericin B delivered as a locally prepared lipid emulsion or in liposomes reduced nephrotoxicity to a similar degree, by 18.4% and 18.1% respectively.
Journal ArticleDOI

Community-based interventions for detection and management of diabetes and hypertension in underserved communities: a mixed-methods evaluation in Brazil, India, South Africa and the USA.

TL;DR: Findings from Brazil and the USA indicate that the HealthRise model has the potential to improve patient outcomes and cannot deliver its full potential if sociodemographic and health system barriers are not addressed in tandem.
Journal ArticleDOI

Cohort study for evaluation of dose omission without justification in a teaching general hospital in Bahia, Brazil

TL;DR: Factors such as the deficit of nursing staff and clinical pharmacists and a weak medication dispensing system, probably contributed to incidence detected and improved the sensibility of the method for detecting omission errors.
Journal ArticleDOI

Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.

TL;DR: There is some evidence in the literature to support the use of L-AmB formulations for the initial treatment of leishmaniasis, but there is a lack of good-quality comparative clinical studies with reliable economic analysis to support this use.